Harnesses immunity that transforms elite responder clues into tailored antibody treatments targeting tumor-suppressive pathways.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Overview
OncoResponse, Inc. is a clinical-stage immuno-oncology company that discovers and develops fully human monoclonal antibodies using insights from elite cancer responders and a proprietary B-cell discovery platform. It enables tailored antibody therapeutics that activate the immune system against tumors by targeting suppressive immune pathways.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
OncoResponse Management Team
Investors
Alexandria Venture Investments
ARCH Venture Partners
Baxalta Ventures
Canaan Partners
GreatPoint Ventures
Helsinn Investment Fund
HT Family Office
Qatar Investment Authority (QIA)
Redmile Group
RiverVest Venture Partners LLC
Shire Pharmaceuticals, Inc.
The University of Texas – MD Anderson
William Marsh Rice University
OncoResponse Valuations & Financials
View real-time NPM data on OncoResponse stock including daily OncoResponse stock price estimates, valuation history, and historical share price information. Access OncoResponse financing rounds, secondary trade levels, cap table data, and private company comparable transactions. Use NPM's private company valuation database to track OncoResponse pricing across six independent market signals. Looking for private company due diligence data sources on OncoResponse? Get in touch to learn more.
Similar Companies
like OncoResponse
Be Biopharma
Healthcare & Life Sciences
Develops engineered B cell medicines and protein-based therapies to treat serious diseases, focusing on innovative therapeutic solutions.
Dewpoint
Healthcare & Life Sciences
Develops therapies targeting protein phase transitions in cells, using biomolecular condensate technology to advance drug discovery and treatment.
Biobot Analytics
Healthcare & Life Sciences
A health data company that monitors wastewater to predict health threats, providing actionable insights for disease control and resource management.
Appia Bio
Healthcare & Life Sciences
Develops universal cell therapies using engineered iNKT cells from stem cells to create accessible, off-the-shelf treatments.
Persist AI
Healthcare & Life Sciences
Develops long-acting injectable drug formulations through screening, testing, and scale-up to solve clearance and stability issues.
Potrero
Healthcare & Life Sciences
Develops technology that monitors patient data in real time to detect complications early and support clinical decision-making.
Exthymic
Healthcare & Life Sciences
Develops decentralized cell therapy manufacturing solutions to enhance accessibility and scalability of autologous treatments.
ShiraTronics
Healthcare & Life Sciences
Develops innovative neuromodulation technology for migraine therapy, focusing on clinical testing of implantable medical devices.
StimAire
Healthcare & Life Sciences
Develops non-surgical neural stimulation technology using wearables and injectables to treat medical conditions without invasive procedures.
FAQ
We have answers
OncoResponse stock does not trade on public stock exchanges. OncoResponse stock is considered a private security and you need to be an accredited investor to trade shares. To invest in OncoResponse stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
OncoResponse Stock does not trade on public stock exchanges. In order to sell OncoResponse shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
OncoResponse does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the NPM Data and Intelligence database from Nasdaq Private Market, you can view OncoResponse share price and other valuable private market data.
Read more about secondary market private company stock prices:
There is no ticker symbol for OncoResponse stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell OncoResponse stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in OncoResponse stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
OncoResponse is a private company and has not had an IPO. There is currently no OncoResponse IPO price. Get started to begin exploring the Nasdaq Private Market Data and Intelligence database and gain access to actionable data related to OncoResponse IPO.
Learn more about Data and Intelligence private company stock data for institutional investors on the on the NPM Data and Intelligence Product Page.
